AcuityMD – Weekly Recap

AcuityMD featured prominently this week with a series of case studies and conference-focused updates that underline its push deeper into MedTech commercial intelligence. The company highlighted how its platform helped Route 92 Medical scale its commercial organization, reporting major gains in forecasting, onboarding, and sales-cycle efficiency.

According to AcuityMD’s materials, Route 92 Medical doubled its commercial team while using the platform to build needed infrastructure for visibility and consistency. Reported outcomes included forecast accuracy of about 97% and new hires ramping 10 times faster, with training on pipeline and forecasting completed within roughly two months.

The case study also cited a reduction in deal cycles from an estimated nine to 12 months down to about three months, suggesting meaningful improvements in sales execution for customers adopting AcuityMD’s tools. Route 92’s VP of Commercial Excellence described a move from “gut feel” to data-driven confidence, positioning the software as foundational to running the business.

Beyond the Route 92 example, AcuityMD focused on sector trends that could broaden its addressable market. At ASCA 2026, the company emphasized the shift of higher-acuity procedures into ambulatory surgery centers and the resulting need for granular data on procedure mix, scheduling, and sales strategy.

AcuityMD signaled that its analytics and market-intelligence capabilities are being aligned to track what is happening inside ASCs as procedure volumes and complexity rise. This may help MedTech manufacturers and vendors refine territory planning and account targeting in a structurally growing outpatient setting.

In parallel, AcuityMD showcased its AcuityAI platform at the AUA 2026 urology conference, targeting commercial teams in procedure-driven specialties. The company positioned AcuityAI as a tool to identify high-growth urologists, underserved accounts, and priority opportunities to drive more efficient sales coverage.

These urology-focused efforts highlight an ongoing strategy to deliver specialized, AI-enabled sales intelligence that can support market share gains for device makers. AcuityMD is also leveraging industry conferences as key go-to-market channels to build brand awareness, generate pipeline, and demonstrate product capabilities directly to MedTech sales and marketing teams.

While the disclosures do not include financial metrics or customer counts, the week’s updates collectively point to product traction, expanding use cases, and deeper engagement in high-growth MedTech niches. Overall, AcuityMD’s recent activity suggests a steadily strengthening position in data-driven commercial enablement for the healthcare technology market.